Clopidogrel, Poor Metabolism of
8
1
1
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
25%
2 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
CES1 Carriers in the PAPI Study
PTRG-DES Consortium
Aggregometry in Elderlies With Hip Fracture and Receiving Clopidogrel
Clopidogrel Resistance in Stroke Patients From Different Ethnicities
Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity
Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease